D. Tseneklidou-Stoeter

发表

Safety and efficacy of BAY 81‐8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme

J. Oldenburg, J. Windyga, S. Lalezari, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years

E. Santagostino, J. Mahlangu, S. Lalezari, 2020, European journal of haematology.

Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

J. Mahlangu, Depei Wu, C. Truica, 2015, Journal of thrombosis and haemostasis : JTH.

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

C. Négrier, P. Holme, I. Pabinger, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Patient characteristics that influence efficacy of prophylaxis with rFVIII‐FS three times per week: a subgroup analysis of the LIPLONG study

A. Coppola, S. Lalezari, J. Ingerslev, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial

R. Ljung, H. Glosli, M. Mancuso, 2022, Thrombosis and Haemostasis.

Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study.

B. Kerlin, R. Ljung, V. Blanchette, 2020, Thrombosis Research.

PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A

K. Fischer, M. Mancuso, G. Kenet, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and safety of BAY 81‐8973, a full‐length recombinant factor VIII: results from the LEOPOLD I trial

J. Oldenburg, K. Saxena, S. Lalezari, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

BAY 81‐8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial

R. Ljung, M. Mancuso, G. Kenet, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial

Depei Wu, Yongqiang Zhao, N. Church, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Extended Interval Prophylaxis with Bay 94-9027 for > 4 Years Leads to Median Spontaneous Annualized Bleeding Rates < 1 in the Protect VIII Extension

M. Simpson, S. Lalezari, S. Ahuja, 2018, Blood.

BAY 81‐8973, a full‐length recombinant factor VIII: results from an International comparative laboratory field study

Y. Katterle, S. Kitchen, H. Beckmann, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.